

*Hong Kong Exchanges and Clearing Limited and The Stock Exchange of Hong Kong Limited take no responsibility for the contents of this announcement, make no representation as to its accuracy or completeness and expressly disclaim any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this announcement.*



**Genscript Biotech Corporation**

**金斯瑞生物科技股份有限公司\***

*(Incorporated in the Cayman Islands with limited liability)*

**(Stock code: 1548)**

**COMPLETION OF (1) THE DEEMED DISPOSAL OF BSJ NANJING;  
(2) SUBSCRIPTION OF NEW SHARES OF LEGEND CAYMAN;  
AND  
(3) CONNECTED TRANSACTION IN RELATION TO THE  
DEEMED DISPOSAL OF LEGEND CAYMAN**

Reference is made to the announcement of the Company dated 28 June 2017 in relation to the Deemed Disposal of BSJ Nanjing, Subscription of New Shares of Legend Cayman, and Connected Transaction in relation to the Deemed Disposal of Legend Cayman (the “**June Announcement**”), the supplemental announcement of the Company dated 17 July 2017 (the “**July Announcement**”), the announcement of the Company dated 28 August 2017 in relation to the Additional Subscription of New Shares of Legend Cayman and Connected Transaction in relation to the Deemed Disposal of Legend Cayman (the “**August Announcement**”), the voluntary announcement of the Company dated 13 September 2017 in relation to extension of BSJ Conditions Fulfillment Date in relation to the BSJ Capital Increase Agreement (the “**September Announcement**”), and the supplemental announcements of the Company dated 9 October 2017 and 16 October 2017 (the “**October Agreements**”, together with the June Announcement, the July Announcement, the August Announcement and the September Announcement, the “**Announcements**”). Capitalized terms used in this announcement shall have the same meanings as those defined in the Announcements.

The Board is pleased to announce that on 19 October 2017, all of the BSJ Conditions set out in the BSJ Capital Increase Agreement have been satisfied, and the BSJ Capital Increase has been completed. Accordingly, as of the date of this announcement, (i) the registered capital of BSJ Nanjing was increased from US\$29,000,000.00 to US\$31,321,713.44 and the equity interest in BSJ Nanjing is now directly held as to 92.590% by BSJ HK and indirectly held as to 0.074%, 0.235%, 0.707%, 1.650%, 2.358%, and 2.386% by GS Corp, Ms. Huang, Mr. Li, Ms. Wang, Mr. Zhang, and Mr. Hao, respectively, through the PRC Fund, and (ii) BSJ Nanjing has become an indirect non-wholly owned subsidiary of the Company.

The Board is also pleased to announce that on the same day, all of the Legend Conditions set out in the Legend Share Subscription Agreement and the Supplemental Legend Share Subscription Agreement have been satisfied, and both the Legend Share Allotment and Issuance and the Additional Legend Share Allotment and Issuance have been completed. Accordingly, as of the date of this announcement, (i) Legend Cayman is now directly held as to 84.84% by the Company and 15.16% by the Cayman Fund, and (ii) Legend Cayman has become a direct non-wholly owned subsidiary of the Company.

Immediately after the Legend Completion, by written shareholder resolutions of Legend Cayman made on 19 October 2017, (i) 16,968,000 and 3,032,000 issued ordinary shares of a nominal or par value of USD0.001 each in the capital of Legend Cayman held by the Company and the Cayman Fund, respectively, were sub-divided into 169,680,000 and 30,320,000 ordinary shares of a nominal or par value of USD0.0001 each, respectively, and (ii) 30,000,000 authorised but unissued ordinary shares of a nominal or par value of USD0.001 each in the capital of Legend Cayman were sub-divided into 300,000,000 ordinary shares of a nominal or par value of USD0.0001 each (collectively, “**Legend Cayman Share Subdivision**”). As a result of the Legend Cayman Share Subdivision, 169,680,000 and 30,320,000 ordinary shares of a nominal or par value of USD0.0001 each of Legend Cayman are held by the Company and the Cayman Fund, respectively, representing 84.84% and 15.16% of the issued share capital of Legend Cayman, respectively.

By Order of the Board  
**Genscript Biotech Corporation**  
**Dr. Zhang Fangliang**  
*Chairman and Chief Executive Officer*

Hong Kong, 20 October 2017

*As at the date of this announcement, our executive Directors are Dr. ZHANG Fangliang, Ms. WANG Ye, and Mr. MENG Jiange; our non-executive Directors are Dr. WANG Luquan, Mr. HUANG Zuie-Chin, and Mr. PAN Yuexin; and our independent non-executive Directors are Mr. GUO Hongxin, Mr. DAI Zumian, and Ms. ZHANG Min.*

\* *For identification purposes only*